Patient and transplantation characteristics
| Characteristics . | All patients . | No PT-CY . | PT-CY . |
|---|---|---|---|
| Patients, n | 228 | 126 | 102 |
| Female, n (%) | 95 (42) | 50 (40) | 45 (44) |
| Median age at transplant, y (IQR*) | 56 (46-64) | 54 (45 – 63) | 60 (50-65) |
| Year of transplant, n (%) | |||
| 2007-2011 | 91 (40) | 81 (64) | 10 (10) |
| 2012-2014 | 137 (60) | 45 (36) | 92 (90) |
| World Health Organization classification at transplant, n (%) | |||
| RCMD | 31 (13) | 17 (13) | 14 (14) |
| RA/RARS/del5q | 12 (5.2) | 7 (6) | 5 (5) |
| RAEB-1 | 35 (15) | 21 (17) | 14 (14) |
| RAEB-2 | 66 (29) | 34 (27) | 32 (32) |
| Transformed in AML | 84 (36) | 47 (37) | 37 (36) |
| Median time from diagnosis to transplant, mo (IQR) | 11 (6-26) | 10 (6-21) | 13 (7-28) |
| Percent blast at time of transplant, n (%) | |||
| <5% | 106 (47) | 60 (49) | 46 (45) |
| ≥5% | 118 (53) | 62(51) | 56 (55) |
| Missing | 4 | 4 | 0 |
| Status at transplant, n (%) | |||
| Untreated | 2 (1) | 2 (2) | 0 |
| Treated and in CR | 69 (36) | 39 (39) | 30 (34) |
| Treated and not in CR | 119 (62) | 59 (59) | 58 (66) |
| Missing | 40 | 26 | 14 |
| Donor/recipient sex match, n (%) | |||
| Female/male | 52 (23) | 32 (25) | 20 (20) |
| Other combination | 178 (77) | 94 (75) | 82 (80) |
| Number of HLA mismatches, n (%) | |||
| 1 | 49 (21) | 48 (38) | 1 (1) |
| ≥2 | 179 (78) | 78 (62) | 101 (99) |
| Donor/recipient CMV match, n (%) | |||
| Negative/negative | 33 (15) | 21 (18) | 12 (12) |
| Positive/negative | 12 (5) | 6 (5) | 6 (6) |
| Negative/positive | 41 (18) | 25 (21) | 16 (16) |
| Positive/positive | 133 (61) | 66 (56) | 67 (66) |
| Source of stem cells, n (%) | |||
| Bone marrow | 73 (32) | 29 (23) | 44 (43) |
| Peripheral blood | 155 (68) | 97 (77) | 58 (57) |
| Conditioning regimen, n (%) | |||
| Reduced intensity | 118 (52) | 64 (51) | 54 (53) |
| Myeloablative | 110 (48) | 62 (49) | 48 (47) |
| Total body irradiation, n (%) | 62 (27) | 31 (25) | 31 (30) |
| Ex vivo TCD*, n (%) | 34 (15) | 33 (26) | 1 (1) |
| In vivo TCD, n (%) | |||
| Antithymoglobulin | 98 (43) | 96 (76) | 2 (2) |
| Alemtuzumab | 8 (3) | 8 (6) | 0 |
| Characteristics . | All patients . | No PT-CY . | PT-CY . |
|---|---|---|---|
| Patients, n | 228 | 126 | 102 |
| Female, n (%) | 95 (42) | 50 (40) | 45 (44) |
| Median age at transplant, y (IQR*) | 56 (46-64) | 54 (45 – 63) | 60 (50-65) |
| Year of transplant, n (%) | |||
| 2007-2011 | 91 (40) | 81 (64) | 10 (10) |
| 2012-2014 | 137 (60) | 45 (36) | 92 (90) |
| World Health Organization classification at transplant, n (%) | |||
| RCMD | 31 (13) | 17 (13) | 14 (14) |
| RA/RARS/del5q | 12 (5.2) | 7 (6) | 5 (5) |
| RAEB-1 | 35 (15) | 21 (17) | 14 (14) |
| RAEB-2 | 66 (29) | 34 (27) | 32 (32) |
| Transformed in AML | 84 (36) | 47 (37) | 37 (36) |
| Median time from diagnosis to transplant, mo (IQR) | 11 (6-26) | 10 (6-21) | 13 (7-28) |
| Percent blast at time of transplant, n (%) | |||
| <5% | 106 (47) | 60 (49) | 46 (45) |
| ≥5% | 118 (53) | 62(51) | 56 (55) |
| Missing | 4 | 4 | 0 |
| Status at transplant, n (%) | |||
| Untreated | 2 (1) | 2 (2) | 0 |
| Treated and in CR | 69 (36) | 39 (39) | 30 (34) |
| Treated and not in CR | 119 (62) | 59 (59) | 58 (66) |
| Missing | 40 | 26 | 14 |
| Donor/recipient sex match, n (%) | |||
| Female/male | 52 (23) | 32 (25) | 20 (20) |
| Other combination | 178 (77) | 94 (75) | 82 (80) |
| Number of HLA mismatches, n (%) | |||
| 1 | 49 (21) | 48 (38) | 1 (1) |
| ≥2 | 179 (78) | 78 (62) | 101 (99) |
| Donor/recipient CMV match, n (%) | |||
| Negative/negative | 33 (15) | 21 (18) | 12 (12) |
| Positive/negative | 12 (5) | 6 (5) | 6 (6) |
| Negative/positive | 41 (18) | 25 (21) | 16 (16) |
| Positive/positive | 133 (61) | 66 (56) | 67 (66) |
| Source of stem cells, n (%) | |||
| Bone marrow | 73 (32) | 29 (23) | 44 (43) |
| Peripheral blood | 155 (68) | 97 (77) | 58 (57) |
| Conditioning regimen, n (%) | |||
| Reduced intensity | 118 (52) | 64 (51) | 54 (53) |
| Myeloablative | 110 (48) | 62 (49) | 48 (47) |
| Total body irradiation, n (%) | 62 (27) | 31 (25) | 31 (30) |
| Ex vivo TCD*, n (%) | 34 (15) | 33 (26) | 1 (1) |
| In vivo TCD, n (%) | |||
| Antithymoglobulin | 98 (43) | 96 (76) | 2 (2) |
| Alemtuzumab | 8 (3) | 8 (6) | 0 |
Twenty-nine patients received ex vivo and in vivo TCD.
IQR, interquartile range; RA, refractory anemia; RAEB, refractory anemia with excess blast according to World Health Organization definition; RARS, refractory anemia with ring sideroblasts; RCMD, refractory cytopenia with myelodysplasia.